4种系统治疗史蒂文斯–约翰逊综合征和中毒性表皮坏死松解症的网状Meta分析
Network Meta-Analysis of 4 Systemic Treatments for Stevenson-Johnson Syndrome and Toxic Epidermal Necrolysis
DOI: 10.12677/ACM.2020.105107, PDF,   
作者: 刘 珂, 袁飞飞:青岛大学,山东 青岛;李 洋:青岛市立医院皮肤科,山东 青岛;乔 霞:青岛大学附属医院整形美容科,山东 青岛;陈官芝*:青岛大学附属医院皮肤科,山东 青岛
关键词: 史蒂文斯–约翰逊综合征中毒性表皮坏死松解症网状Meta分析Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Network Meta-Analysis
摘要: 目的:运用网状Meta比较4种系统治疗和支持性治疗史蒂文斯–约翰逊综合征和中毒性表皮坏死松解症的疗效。方法:检索Pubmed、Embase和Cochrane数据库,时间设定为1994年至2019年7月。根据纳入排除标准完成文献筛选、数据提取及质量评价,使用R软件和STATA 14.0进行分析。结果:数据库共检索到12,278篇文章,最终纳入17篇文献,共541名患者。在减少完全再上皮化时间方面:环孢素优于激素,差异有统计学意义(P < 0.05)。SUCRA排序结果前三名依次为环孢素、IVIG联合激素、支持性治疗。在减少平均住院日方面:环孢素优于单用IVIG,结果有统计学意义(P < 0.05)。SUCRA排序结果前三名依次为环孢素、IVIG联合激素、支持性治疗。结论:本次网状Meta分析结果为临床应用环孢素治疗SJS/TEN提供了依据。
Abstract: Objective: A network meta-analysis was used to compare the efficacy of four systemic and support-ive treatments for Stevenson-Johnson syndrome and toxic epidermal necrolysis. Methods: Pubmed, Embase and Cochrane databases were retrieved from 1994 to July 2019. Literature screening, data extraction and quality evaluation were completed according to inclusion and exclusion criteria, and R software and STATA 14.0 were used for analysis. A total of 12,278 articles were retrieved from the database and 17 articles were eventually included, totaling 541 patients. In terms of reducing the time of complete reepithelialization, cyclosporine was superior to glucocorticoid, and the difference was statistically significant (P < 0.05). The top three results of SUCRA sequencing were cyclosporine, IVIG combined with glucocorticoid and supportive therapy. Cyclosporine was superior to IVIG alone in reducing average hospital stay, and the results were statistically significant (P < 0.05). The top three results of SUCRA sequencing were cyclosporine, IVIG combined hormone and supportive therapy. Conclusion: The results of this network meta-analysis provide a basis for the clinical application of cyclosporine in the treatment of SJS/TEN.
文章引用:刘珂, 李洋, 乔霞, 袁飞飞, 陈官芝. 4种系统治疗史蒂文斯–约翰逊综合征和中毒性表皮坏死松解症的网状Meta分析[J]. 临床医学进展, 2020, 10(5): 683-693. https://doi.org/10.12677/ACM.2020.105107

参考文献

[1] Dodiuk-Gad, R.P., Chung, W.H., Valeyrie-Allanore, L., et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. American Journal of Clinical Dermatology, 16, 475-493. [Google Scholar] [CrossRef] [PubMed]
[2] 曾宪涛, 黄伟, 田国祥. Meta分析系列之九: Meta分析的质量评价工具[J]. 中国循证心血管医学杂志, 2013, 5(1): 3-5.
[3] Singh, G.K., Chatterjee, M. and Verma, R. (2013) Cyclosporine in Stevens Johnson Syndrome and Toxic Epidermal Necrolysis and Retrospective Comparison with Sys-temic Corticosteroid. Indian Journal of Dermatology, Venereology and Leprology, 79, 686-692. [Google Scholar] [CrossRef] [PubMed]
[4] Kirchhof, M.G., Miliszewski, M.A., Sikora, S., et al. (2014) Ret-rospective Review of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Treatment Comparing Intravenous Im-munoglobulin with Cyclosporine. Journal of the American Academy of Dermatology, 71, 941-947. [Google Scholar] [CrossRef] [PubMed]
[5] Lee, H.Y., Fook-Chong, S., Koh, H.Y., et al. (2017) Cyclosporine Treatment for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Retrospective Analysis of a Cohort Treated in a Specialized Referral Center. Journal of the American Academy of Dermatology, 76, 106-113. [Google Scholar] [CrossRef] [PubMed]
[6] Mohanty, S., Das, A., Ghosh, A., et al. (2017) Effectiveness, Safety and Tolerability of Cyclosporine versus Supportive Treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Record-Based Study. Indian Journal of Dermatology, Venereology and Leprology, 83, 312-316. [Google Scholar] [CrossRef
[7] Stella, M., Clemente, A., Bollero, D., et al. (2007) Toxic Epi-dermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS): Experience with High-Dose Intravenous Immuno-globulins and Topical Conservative Approach. A Retrospective Analysis. Burns: Journal of the International Society for Burn Injuries, 33, 452-459. [Google Scholar] [CrossRef] [PubMed]
[8] Yang, Y., Xu, J., Li, F., et al. (2009) Combination Therapy of Intravenous Immunoglobulin and Corticosteroid in the Treatment of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: A Retrospective Comparative Study in China. International Journal of Dermatology, 48, 1122-1128. [Google Scholar] [CrossRef] [PubMed]
[9] Zhu, Q.Y., Ma, L., Luo, X.Q., et al. (2012) Toxic Epi-dermal Necrolysis: Performance of SCORTEN and the Score-Based Comparison of the Efficacy of Corticosteroid Therapy and Intravenous Immunoglobulin Combined Therapy in China. Journal of Burn Care & Research, 33, e295-e308. [Google Scholar] [CrossRef
[10] Jagadeesan, S., Sobhanakumari, K., Sadanandan, S.M., et al. (2013) Low Dose Intravenous Immunoglobulins and Steroids in Toxic Epidermal Necrolysis: A Prospective Comparative Open-Labelled Study of 36 Cases. Indian Journal of Dermatology, Venereology and Leprology, 79, 506-511. [Google Scholar] [CrossRef] [PubMed]
[11] Lalosevic, J., Nikolic, M., Gajic-Veljic, M., et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Single-Center Experience. International Journal of Dermatology, 54, 978-984. [Google Scholar] [CrossRef] [PubMed]
[12] Sato, S., Kanbe, T., Tamaki, Z., et al. (2018) Clinical Features of Ste-vens-Johnson Syndrome and Toxic Epidermal Necrolysis. Pediatrics International, 60, 697-702. [Google Scholar] [CrossRef] [PubMed]
[13] Léauté-Labrèze, C., Lamireau, T., Chawki, D., et al. (2000) Diagnosis, Classification, and Management of Erythema Multiforme and Stevens-Johnson Syndrome. Archives of Disease in Childhood, 83, 347-352. [Google Scholar] [CrossRef] [PubMed]
[14] Brand, R. and Rohr, J.B. (2000) Toxic Epidermal Necrolysis in Western Australia. The Australasian Journal of Dermatology, 41, 31-33. [Google Scholar] [CrossRef] [PubMed]
[15] Koh, M.J. and Tay, Y.K. (2010) Stevens-Johnson Syn-drome and Toxic Epidermal Necrolysis in Asian Children. Journal of the American Academy of Dermatology, 62, 54-60. [Google Scholar] [CrossRef] [PubMed]
[16] Chatproedprai, S., Wutticharoenwong, V., Tempark, T., et al. (2018) Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. Dermatology Research and Practice, 2018, Article ID: 3061084. [Google Scholar] [CrossRef] [PubMed]
[17] Brown, K.M., Silver, G.M., Halerz, M., et al. (2004) Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference? The Journal of Burn Care & Rehabilitation, 25, 81-88. [Google Scholar] [CrossRef
[18] Shortt, R., Gomez, M., Mittman, N., et al. (2004) Intravenous Immunoglobulin Does Not Improve Outcome in Toxic Epidermal Necrolysis. The Journal of Burn Care & Rehabilitation, 25, 246-255. [Google Scholar] [CrossRef
[19] Gravante, G., Delogu, D., Marianetti, M., et al. (2007) Toxic Epidermal Necrolysis and Steven Johnson Syndrome: 11-Years Experience and Outcome. European Review for Medical and Pharmacological Sciences, 11, 119-127.
[20] Wolkenstein, P., Latarjet, J., Roujeau, J.C., et al. (1998) Randomised Comparison of Thalidomide versus Placebo in Toxic Epidermal Necrolysis. The Lancet (London, England), 352, 1586-1589. [Google Scholar] [CrossRef
[21] Viard, I., Wehrli, P., Bullani, R., et al. (1998) Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin. Science (New York, NY), 282, 490-493. [Google Scholar] [CrossRef] [PubMed]
[22] Kim, K.J., Lee, D.P., Suh, H.S., et al. (2005) Toxic Epidermal Necrolysis: Analysis of Clinical Course and SCORTEN-Based Comparison of Mortality Rate and Treatment Modalities in Korean Patients. Acta Dermato-Venereologica, 85, 497-502.
[23] Huang, Y.C., Chien, Y.N., Chen, Y.T., et al. (2016) Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis. Giornale Italiano di Dermatologia e Venereologia, 151, 515-524.